Genex Pharmaceutical, Inc.
Other OTCTotal Valuation
Genex Pharmaceutical, Inc. carries a market capitalization of 1,788.00, placing it among publicly traded companies globally.
| Market Cap | 1,788.00 |
| Enterprise Value | N/A |
Share Statistics
Genex Pharmaceutical, Inc. currently has 17.85M shares outstanding.
| Shares Outstanding | 17.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Genex Pharmaceutical, Inc. trades at a trailing price-to-earnings ratio of 15.11. The price-to-sales ratio is 1.60, and the price-to-book ratio stands at 2.05.
| PE Ratio | 15.11 |
| PS Ratio | 1.60 |
| PB Ratio | 2.05 |
| P/TBV Ratio | 1.09 |
| P/FCF Ratio | 9.76 |
| P/OCF Ratio | 9.77 |
Financial Position
Genex Pharmaceutical, Inc. maintains a current ratio of 0.62, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.62 |
| Quick Ratio | 0.17 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | 14.25 |
| Return on Assets (ROA) | 4.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.77 |
Taxes
Over the trailing twelve months, Genex Pharmaceutical, Inc. has paid 391,037.00 in income taxes, reflecting an effective tax rate of 53.30.
| Income Tax | 391,037.00 |
| Effective Tax Rate | 53.30 |
Stock Price Statistics
Genex Pharmaceutical, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Genex Pharmaceutical, Inc. generated 3.24M in revenue and converted that into 342,549.00 in net income, yielding earnings per share of 0.02. EBITDA reached 718,267.00, while operating income came in at 662,128.00.
| Revenue | 3.24M |
| Gross Profit | 2.87M |
| Operating Income | 662,128.00 |
| Pretax Income | 733,586.00 |
| Net Income | 342,549.00 |
| EBITDA | 718,267.00 |
| EBIT | 662,128.00 |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
Total book value stands at 2.53M, with working capital of -1.34M providing operational flexibility.
| Cash & Cash Equivalents | 430,124.00 |
| Total Debt | N/A |
| Net Debt | -430,124.00 |
| Equity (Book Value) | 2.53M |
| Book Value Per Share | 0.14 |
| Working Capital | -1.34M |
Cash Flow
Genex Pharmaceutical, Inc. produced 529,657.00 in operating cash flow over the past twelve months. After subtracting -579.00 in capital expenditures, free cash flow totaled 529,078.00 - equivalent to 0.03 per share.
| Operating Cash Flow | 529,657.00 |
| Capital Expenditures | -579.00 |
| Free Cash Flow | 529,078.00 |
| FCF Per Share | 0.03 |
Margins
Genex Pharmaceutical, Inc. operates with a gross margin of 88.80, reflecting its pricing power and cost economics. The operating margin of 20.45 and net profit margin of 10.58 provide insight into operational efficiency.
| Gross Margin | 88.80 |
| Operating Margin | 20.45 |
| Pretax Margin | 22.66 |
| Profit Margin | 10.58 |
| EBITDA Margin | 22.19 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -30.28 |
| FCF Yield | 10.25 |
Stock Splits
Genex Pharmaceutical, Inc.'s most recent stock split took place on July 1, 2004 with a 1:4 split ratio.
| Last Split Date | 7/1/2004 |
| Split Ratio | 1:4 |
Scores
Genex Pharmaceutical, Inc. posts an Altman Z-Score of 1.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.64 |